<div id="readability-page-1"><p>Fulcrum Capital LLC trimmed its stake in  Stryker Co. (NYSE:SYK - Free Report) by 69.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor  owned 588 shares of the medical technology company's stock after selling 1,327 shares during the quarter. Fulcrum Capital LLC's holdings in Stryker were worth $219,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p><ul><li>If You Could Only Hold 3 Investments for Life, Consider These</li></ul><p>A number of other hedge funds have also made changes to their positions in SYK. Kohmann Bosshard Financial Services LLC bought a new position in  Stryker during the fourth quarter valued at approximately $25,000.  Capital A Wealth Management LLC acquired a new position in  Stryker during the fourth quarter valued at approximately $26,000.  Rakuten Securities Inc. grew its holdings in  Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after purchasing an additional 68 shares during the last quarter.  Centricity Wealth Management LLC acquired a new position in  Stryker during the fourth quarter valued at approximately $30,000.  Finally, BankPlus Trust Department acquired a new position in  Stryker during the fourth quarter valued at approximately $33,000. 77.09% of the stock is owned by hedge funds and other institutional investors. </p><h2>Analysts Set New Price Targets</h2><p>Several equities analysts have commented on the company. JMP Securities  reiterated a &#34;market perform&#34; rating on shares of Stryker in a report on Monday, May 5th. Sanford C. Bernstein  set a $450.00 price objective on shares of Stryker in a research note on Monday, May 5th. Evercore ISI lowered their price objective on shares of Stryker from $400.00 to $390.00 and set an &#34;outperform&#34; rating on the stock in a research note on Friday, May 2nd. Roth Mkm raised their price objective on shares of Stryker from $405.00 to $456.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, May 2nd. Finally, Argus  set a $450.00 price objective on shares of Stryker in a research note on Monday, February 3rd. Five analysts have rated the stock with a hold rating and fifteen have assigned  a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $427.30.</p><ul><li>3 Stocks Helping to Bring AI to Healthcare</li></ul><p><b>View Our Latest Stock Report on Stryker</b></p><h2>Insider Buying and Selling at Stryker</h2><p>In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the transaction, the director now directly owns 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this link. Company insiders own  5.20% of the company's stock. </p><h2>Stryker Stock Up 0.1%</h2><ul><li>Stryker’s Acquisition Spree: Double-Digit Growth on the Horizon</li></ul><p>SYK opened at $382.86 on Friday. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm's fifty day moving average price is $368.77 and its two-hundred day moving average price is $376.22. The company has a market capitalization of $146.13 billion, a P/E ratio of 49.34, a P/E/G ratio of 2.93 and a beta of 0.93. </p><p>Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The business's revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.50 earnings per share.  On average, analysts anticipate that  Stryker Co. will post 13.47 EPS for the current year. </p><h2>Stryker Announces Dividend</h2><p>The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. Stryker's payout ratio is presently 45.41%. </p><h2>About Stryker</h2> (Free Report)<p>Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Stryker</li><li>What is the Dogs of the Dow Strategy? Overview and Examples</li><li>AXON: Competition Intensifies as Motorola Makes $4.4B Acquisition</li><li>What is the Shanghai Stock Exchange Composite Index?</li><li>MarketBeat Week in Review – 05/26 - 05/30</li><li>The Risks of Owning Bonds</li><li>Nike’s Amazon Expansion Could Signal a Turnaround in 2025</li></ul><p><strong>Want to see what other hedge funds are holding SYK?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Stryker Right Now?</h2><p>Before you consider Stryker, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.</p><p>While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Fulcrum Capital LLC reduced its stake in Stryker Co. (NYSE:SYK) by 69.3% in Q1, now holding 588 shares valued at $219,000. Other hedge funds also adjusted their positions. Analysts have set various price targets, with a consensus target of $427.30. Stryker's stock opened at $382.86, with a market cap of $146.13 billion. The company reported Q1 earnings of $2.84 per share, exceeding estimates, and announced a quarterly dividend of $0.84 per share to be paid on July 31.</p>

Stryker Co. (NYSE:SYK) Stock Holdings Lessened by Fulcrum Capital LLC